Efficacy of GalNAc C3 siRNAs in factor H-deficient mice with C3 glomerulopathy
Molecular Immunology · 2024
DOI: 10.1016/j.molimm.2024.02.010 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Immunology, 2024. Verfasst von Cristina Zanchi und 11 weiteren Autor:innen. Beteiligte Einrichtung: Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Centro Anna Maria Astori, Science and Technology Park Kilometro Rosso, Bergamo, Italy. Hauptthemen laut MEDLINE: Glomerulonephritis, Membranoproliferative, Kidney Diseases, Hereditary Complement Deficiency Diseases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Silence Therapeutics plc.
Abstract (Originalsprache)
Complement alternative pathway (AP) dysregulation drives C3 glomerulopathy (C3G), a rare renal disorder characterized by glomerular C3 deposition and glomerular damage, for which no effective treatments are available. Blockade of complement C3 is emerging as a viable therapeutic option. In an earlier study we showed that SLN500, a small interfering RNA targeting liver C3 synthesis, was able to limit AP dysregulation and glomerular C3d deposits in mice with partial factor H (FH) deficiency (Cfh+/- mice). Here, we assessed the pharmacological effects of SLN501 - an optimized SLN500 version - in mice with complete FH deficiency (Cfh-/- mice) that exhibit a more severe C3G phenotype. SLN501 effectively prevented liver C3 synthesis, thus limiting AP dysregulation, glomerular C3d deposits and the development of ultrastructural alterations. These data provide firm evidence of the use of siRNA-mediated liver C3 gene silencing as a potential therapy for treating C3G patients with either partial or complete FH loss of function.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Centro Anna Maria Astori, Science and Technology Park Kilometro Rosso, Bergamo, Italy.
- Silence Therapeutics GmbH, Berlin, Germany.
- Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Centro Anna Maria Astori, Science and Technology Park Kilometro Rosso, Bergamo, Italy. Electronic address: ariela.benigni@marionegri.it.
Förderung
- Silence Therapeutics plc
Zitieren
APA
Zanchi, C., Locatelli, M., Cerullo, D., Aumiller, V., Corna, D., Rottoli, D., Schubert, S., Noris, M., Tomasoni, S., Remuzzi, G., Zoja, C., & Benigni, A. (2024). Efficacy of GalNAc C3 siRNAs in factor H-deficient mice with C3 glomerulopathy. Molecular Immunology. https://doi.org/10.1016/j.molimm.2024.02.010
Vancouver
Zanchi C, Locatelli M, Cerullo D, Aumiller V, Corna D, Rottoli D, et al. Efficacy of GalNAc C3 siRNAs in factor H-deficient mice with C3 glomerulopathy. Molecular Immunology. 2024. doi:10.1016/j.molimm.2024.02.010
BibTeX
@article{Zanchi2024,
author = {Zanchi, Cristina and Locatelli, Monica and Cerullo, Domenico and Aumiller, Verena and Corna, Daniela and Rottoli, Daniela and Schubert, Steffen and Noris, Marina and Tomasoni, Susanna and Remuzzi, Giuseppe and Zoja, Carlamaria and Benigni, Ariela},
title = {Efficacy of GalNAc C3 siRNAs in factor H-deficient mice with C3 glomerulopathy},
journal = {Molecular Immunology},
year = {2024},
doi = {10.1016/j.molimm.2024.02.010}
}
EUVIMED